A Phase I Trial of Zevalin Radioimmunotherapy With High-Dose Melphalan and Stem Cell Transplant for Multiple Myeloma View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2005-2018

ABSTRACT

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. A peripheral stem cell transplant using stem cells from the patient may be able to replace blood-forming cells that were destroyed by chemotherapy. Giving monoclonal antibody therapy together with chemotherapy and autologous peripheral stem cell transplant may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of yttrium Y 90 ibritumomab tiuxetan when given together with rituximab, melphalan, and autologous peripheral stem cell transplant in treating patients with previously treated multiple myeloma. Detailed Description OBJECTIVES: Primary - Determine the safety of rituximab, yttrium Y 90 ibritumomab tiuxetan, high-dose melphalan, and autologous peripheral blood stem cell transplantation in patients with previously treated multiple myeloma. - Determine the effect of rituximab and yttrium Y 90 ibritumomab tiuxetan on the clonotypic B-cells at baseline and at B-cell recovery in these patients. Secondary - Determine the response rate and progression factors (time to progression, progression-free survival, and duration of response) in patients treated with this regimen. - Determine the effect of rituximab and yttrium Y 90 ibritumomab tiuxetan on the clonal plasma cells in the blood and marrow prior to high-dose melphalan. OUTLINE: This is a dose-escalation study of yttrium Y 90 ibritumomab tiuxetan. Patients receive rituximab IV followed by a dosimetry dose of indium In 111 ibritumomab tiuxetan IV over 10 minutes on day -22. Patients with acceptable biodistribution receive rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day -14, high-dose melphalan IV over 1 hour on days -2 and -1, and undergo autologous peripheral blood stem cell transplantation on day 0. Patients also receive sargramostim (GM-CSF) subcutaneously beginning on day 0 and continuing until blood counts recover. Cohorts of 3-6 patients receive escalating doses of yttrium Y 90 ibritumomab tiuxetan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Bone marrow, blood, and urine samples are collected at baseline and then periodically during study for biomarker correlative studies. After completion of study treatment, patients are followed every 3 months for 5 years. More... »

URL

https://clinicaltrials.gov/show/NCT00477815

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3048", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. A peripheral stem cell transplant using stem cells from the patient may be able to replace blood-forming cells that were destroyed by chemotherapy. Giving monoclonal antibody therapy together with chemotherapy and autologous peripheral stem cell transplant may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of yttrium Y 90 ibritumomab tiuxetan when given together with rituximab, melphalan, and autologous peripheral stem cell transplant in treating patients with previously treated multiple myeloma.\n\nDetailed Description\nOBJECTIVES: Primary - Determine the safety of rituximab, yttrium Y 90 ibritumomab tiuxetan, high-dose melphalan, and autologous peripheral blood stem cell transplantation in patients with previously treated multiple myeloma. - Determine the effect of rituximab and yttrium Y 90 ibritumomab tiuxetan on the clonotypic B-cells at baseline and at B-cell recovery in these patients. Secondary - Determine the response rate and progression factors (time to progression, progression-free survival, and duration of response) in patients treated with this regimen. - Determine the effect of rituximab and yttrium Y 90 ibritumomab tiuxetan on the clonal plasma cells in the blood and marrow prior to high-dose melphalan. OUTLINE: This is a dose-escalation study of yttrium Y 90 ibritumomab tiuxetan. Patients receive rituximab IV followed by a dosimetry dose of indium In 111 ibritumomab tiuxetan IV over 10 minutes on day -22. Patients with acceptable biodistribution receive rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day -14, high-dose melphalan IV over 1 hour on days -2 and -1, and undergo autologous peripheral blood stem cell transplantation on day 0. Patients also receive sargramostim (GM-CSF) subcutaneously beginning on day 0 and continuing until blood counts recover. Cohorts of 3-6 patients receive escalating doses of yttrium Y 90 ibritumomab tiuxetan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Bone marrow, blood, and urine samples are collected at baseline and then periodically during study for biomarker correlative studies. After completion of study treatment, patients are followed every 3 months for 5 years.", 
    "endDate": "2018-05-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT00477815", 
    "keywords": [
      "I trial", 
      "stem cell transplant", 
      "multiple myeloma", 
      "rationale", 
      "monoclonal antibody", 
      "rituximab", 
      "cancer growth", 
      "different way", 
      "cancer cell", 
      "substance", 
      "radiolabeled monoclonal antibody", 
      "yttrium", 
      "harming normal cell", 
      "drug", 
      "Drug Therapy", 
      "melphalan", 
      "stop", 
      "Homicide", 
      "cell", 
      "stem cell", 
      "patient", 
      "monoclonal antibody therapy", 
      "Phase I trial", 
      "side effect", 
      "dose", 
      "Determine", 
      "safety", 
      "high dose", 
      "peripheral blood stem cell", 
      "baseline", 
      "cell recovery", 
      "response rate", 
      "Disease-Free Survival", 
      "duration", 
      "regimen", 
      "plasma cell", 
      "blood", 
      "bone marrow", 
      "outline", 
      "dose escalation study", 
      "dosimetry", 
      "indium", 
      "IVS", 
      "biodistribution", 
      "Granulocyte-Macrophage Colony-Stimulating Factor", 
      "blood count", 
      "cohort", 
      "maximum tolerated dose", 
      "toxicity", 
      "urine sample", 
      "correlative study", 
      "completion", 
      "study treatment"
    ], 
    "name": "A Phase I Trial of Zevalin Radioimmunotherapy With High-Dose Melphalan and Stem Cell Transplant for Multiple Myeloma", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00477815"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00004.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.48336.3a", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.66875.3a", 
        "type": "Organization"
      }
    ], 
    "startDate": "2005-05-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1038/bmt.2017.164", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091427991", 
          "https://doi.org/10.1038/bmt.2017.164"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00477815"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00477815'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00477815'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00477815'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00477815'


 

This table displays all metadata directly associated to this object as RDF triples.

81 TRIPLES      16 PREDICATES      71 URIs      62 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00477815 schema:about anzsrc-for:3048
2 anzsrc-for:3142
3 schema:description RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. A peripheral stem cell transplant using stem cells from the patient may be able to replace blood-forming cells that were destroyed by chemotherapy. Giving monoclonal antibody therapy together with chemotherapy and autologous peripheral stem cell transplant may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of yttrium Y 90 ibritumomab tiuxetan when given together with rituximab, melphalan, and autologous peripheral stem cell transplant in treating patients with previously treated multiple myeloma. Detailed Description OBJECTIVES: Primary - Determine the safety of rituximab, yttrium Y 90 ibritumomab tiuxetan, high-dose melphalan, and autologous peripheral blood stem cell transplantation in patients with previously treated multiple myeloma. - Determine the effect of rituximab and yttrium Y 90 ibritumomab tiuxetan on the clonotypic B-cells at baseline and at B-cell recovery in these patients. Secondary - Determine the response rate and progression factors (time to progression, progression-free survival, and duration of response) in patients treated with this regimen. - Determine the effect of rituximab and yttrium Y 90 ibritumomab tiuxetan on the clonal plasma cells in the blood and marrow prior to high-dose melphalan. OUTLINE: This is a dose-escalation study of yttrium Y 90 ibritumomab tiuxetan. Patients receive rituximab IV followed by a dosimetry dose of indium In 111 ibritumomab tiuxetan IV over 10 minutes on day -22. Patients with acceptable biodistribution receive rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day -14, high-dose melphalan IV over 1 hour on days -2 and -1, and undergo autologous peripheral blood stem cell transplantation on day 0. Patients also receive sargramostim (GM-CSF) subcutaneously beginning on day 0 and continuing until blood counts recover. Cohorts of 3-6 patients receive escalating doses of yttrium Y 90 ibritumomab tiuxetan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Bone marrow, blood, and urine samples are collected at baseline and then periodically during study for biomarker correlative studies. After completion of study treatment, patients are followed every 3 months for 5 years.
4 schema:endDate 2018-05-01T00:00:00Z
5 schema:keywords Determine
6 Disease-Free Survival
7 Drug Therapy
8 Granulocyte-Macrophage Colony-Stimulating Factor
9 Homicide
10 I trial
11 IVS
12 Phase I trial
13 baseline
14 biodistribution
15 blood
16 blood count
17 bone marrow
18 cancer cell
19 cancer growth
20 cell
21 cell recovery
22 cohort
23 completion
24 correlative study
25 different way
26 dose
27 dose escalation study
28 dosimetry
29 drug
30 duration
31 harming normal cell
32 high dose
33 indium
34 maximum tolerated dose
35 melphalan
36 monoclonal antibody
37 monoclonal antibody therapy
38 multiple myeloma
39 outline
40 patient
41 peripheral blood stem cell
42 plasma cell
43 radiolabeled monoclonal antibody
44 rationale
45 regimen
46 response rate
47 rituximab
48 safety
49 side effect
50 stem cell
51 stem cell transplant
52 stop
53 study treatment
54 substance
55 toxicity
56 urine sample
57 yttrium
58 schema:name A Phase I Trial of Zevalin Radioimmunotherapy With High-Dose Melphalan and Stem Cell Transplant for Multiple Myeloma
59 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00477815
60 schema:sdDatePublished 2019-03-07T15:22
61 schema:sdLicense https://scigraph.springernature.com/explorer/license/
62 schema:sdPublisher N92711d85182c44129c2683070bd196c4
63 schema:sponsor https://www.grid.ac/institutes/grid.48336.3a
64 https://www.grid.ac/institutes/grid.66875.3a
65 schema:startDate 2005-05-01T00:00:00Z
66 schema:subjectOf sg:pub.10.1038/bmt.2017.164
67 schema:url https://clinicaltrials.gov/show/NCT00477815
68 sgo:license sg:explorer/license/
69 sgo:sdDataset clinical_trials
70 rdf:type schema:MedicalStudy
71 N92711d85182c44129c2683070bd196c4 schema:name Springer Nature - SN SciGraph project
72 rdf:type schema:Organization
73 anzsrc-for:3048 schema:inDefinedTermSet anzsrc-for:
74 rdf:type schema:DefinedTerm
75 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
76 rdf:type schema:DefinedTerm
77 sg:pub.10.1038/bmt.2017.164 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091427991
78 https://doi.org/10.1038/bmt.2017.164
79 rdf:type schema:CreativeWork
80 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
81 https://www.grid.ac/institutes/grid.66875.3a schema:Organization
 




Preview window. Press ESC to close (or click here)


...